[Use of Visken-15 for treating hypertension].
The hypotensive effect of visken-15, a blocking agent of the beta-adrenergic receptors, was studied in 7 patients with stage IB hypertensive disease, in 18 with stage IIA, and in 8 patients with stage IIB under conditions of in- and out-patient establishments. A favourable effect was produced in 81.5% of patients who were given one tablet of the drug once or twice a day. Treatment with visken-15 led to a decrease in systolic, diastolic and mean arterial pressure, in the rate of cardiac contractions, and in the blood minute volume at rest, in the orthostatic position, and during physical load. Visken-15 is marked by low toxicity, it is tolerated well and seldom causes side effects. The drug is recommended for the treatment of patients with early stages of hypertensive disease.
D000293:Adolescent; D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D010869:Pindolol / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011187:Posture; D012146:Rest; D013599:Systole / Q000187:drug effects; D013997:Time Factors
D000959:Antihypertensive Agents; D010919:Placebos; D010869:Pindolol
Primenenie Viskena-15 dlia lecheniia bol'nykh gipertonicheskoĭ bolezn'iu.